» Articles » PMID: 33888045

MicroRNA 21 and MicroRNA 155 Levels in Resistant Hypertension, and Their Relationships with Aldosterone

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2021 Apr 23
PMID 33888045
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: MicroRNAs (miRNAs) are non-coding RNA molecules that serve as regulators following gene expression transcription. While studies have investigated the role of miRNAs in the pathogenesis of essential hypertension (HT), very few have considered their place in the pathogenesis of resistant hypertension (RH). The purpose of this study was to investigate levels of miRNA 21 and miRNA 155 in RH and their relationships with aldosterone.

Method: Thirty-two normotensive patients, 30 newly diagnosed HT patients, and 20 RH patients were included in the study. Patients' demographic data were recorded, and office blood pressure measurement and 24-h ambulatory blood pressure monitoring (24-h ABPM) were performed. Blood specimens were collected for miRNA 21, miRNA 155 and aldosterone measurement. MiRNA 21 and miRNA 155 levels in the control and patient groups and their relations with other demographic and biochemical parameters were then subjected to analysis.

Results: No difference was determined in miRNA 155 levels between the groups, but miRNA 21 and aldosterone levels were significantly higher in the RH group ( < 0.001 and <0.05, respectively). At correlation analysis, miRNA 21 exhibited positive correlation with aldosterone, age, office SBP, 24-h ABPM all-day SBP. A 9.6 copy/uL level for miRNA 21 predicted presence or absence of RH with 95% sensitivity and 71% specificity (AUC:0.823, 95% CI (0.72-0.92).

Conclusion: The study results revealed significantly higher miRNA 21 and aldosterone in RH patients than in healthy individuals and newly diagnosed hypertensives.

Citing Articles

Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients.

Tsota M, Giardoglou P, Mentsiou-Nikolaou E, Symianakis P, Kalafati I, Kyriazopoulou-Korovesi A Noncoding RNA. 2024; 10(3).

PMID: 38921830 PMC: 11207086. DOI: 10.3390/ncrna10030033.


Epigenetics of hypertension as a risk factor for the development of coronary artery disease in type 2 diabetes mellitus.

Karabaeva R, Vochshenkova T, Mussin N, Albayev R, Kaliyev A, Tamadon A Front Endocrinol (Lausanne). 2024; 15:1365738.

PMID: 38836231 PMC: 11148232. DOI: 10.3389/fendo.2024.1365738.


The Association of Micro-RNA 21 and Hypertension: A Meta-Analysis.

Xin C, He W, Sun X, Li M, Wang H Glob Heart. 2024; 19(1):41.

PMID: 38708403 PMC: 11067968. DOI: 10.5334/gh.1325.


The pharmaco-epigenetics of hypertension: a focus on microRNA.

Yaacoub S, Boudaka A, AlKhatib A, Pintus G, Sahebkar A, Kobeissy F Mol Cell Biochem. 2024; 479(12):3255-3271.

PMID: 38424404 PMC: 11511726. DOI: 10.1007/s11010-024-04947-9.


Correlation between serum levels of microRNA-21 and inflammatory factors in patients with chronic heart failure.

Li W, Li Y, Jiang F, Liu H Medicine (Baltimore). 2022; 101(38):e30596.

PMID: 36197244 PMC: 9509079. DOI: 10.1097/MD.0000000000030596.


References
1.
Yang Q, Jia C, Wang P, Xiong M, Cui J, Li L . MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation. Int J Cardiol. 2014; 177(3):925-34. DOI: 10.1016/j.ijcard.2014.09.204. View

2.
Lastra G, Syed S, Kurukulasuriya L, Manrique C, Sowers J . Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014; 43(1):103-22. PMC: 3942662. DOI: 10.1016/j.ecl.2013.09.005. View

3.
Liu D, Li S, Zhu Q, Jiang W . The involvement of miR-155 in blood pressure regulation in pregnant hypertension rat via targeting FOXO3a. Eur Rev Med Pharmacol Sci. 2018; 22(20):6591-6598. DOI: 10.26355/eurrev_201810_16133. View

4.
Nosalski R, McGinnigle E, Siedlinski M, Guzik T . Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. Curr Cardiovasc Risk Rep. 2017; 11(4):12. PMC: 5339316. DOI: 10.1007/s12170-017-0537-6. View

5.
Aronow W . Approaches for the Management of Resistant Hypertension in 2020. Curr Hypertens Rep. 2020; 22(1):3. DOI: 10.1007/s11906-019-1013-0. View